Navigation Links
Startup joins UCLA tech incubator to develop technologies for drug discovery, screening
Date:2/25/2010

Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.

Ion channels are proteins in cell membranes that play a central role in generating and transmitting cardiac and neural signals. The channels control the passage of ions into and out of cells; the effects of drugs that act on ion channels can be determined by measuring the flow of ions through these channels. However, conventional measurement technologies, which utilize live cells, are relatively slow and expensive.

A team led by UCLA associate professor of bioengineering Jacob Schmidt has developed a cell-free artificial membrane technology for ion channel measurement that may result in significant savings of time and cost.

This technology has been exclusively licensed by Librede, which was founded in July 2008 by Schmidt and Jason Poulos, Librede's chief technical officer and a co-inventor of the technology. As part of this arrangement, the University of California will earn a royalty on the company's future products.

Librede moved into lab space at the CNSI incubator this month and has access to CNSI core lab facilities such as the Molecular Shared Screening Resource (MSSR) for research and development.

"The CNSI's incubator space is ideal for us," Poulos said. "We have access to state-of-the-art facilities and technical staff that will allow us to rapidly develop our technology and grow our company."

"Although cell-free platforms for ion channel measurement have been used for decades, their cost and expertise requirements have mostly limited their use to scientists," Schmidt said. "We have developed an artificial cell membrane that is inexpensive, easy to use and automatable. We hope that our technology will reduce the cost and time associated with ion channel measurements."

The UCLA on-campus Technology Incubator Program at the CNSI is an innovative resource with a mission to help accelerate the growth of entrepreneurial startup companies and early-stage technology research projects that originate at UCLA. The incubator offers shared, flexible lab space dedicated to housing eight to 10 early-stage incubation projects for short periods of time.


'/>"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Texas invests record $3.5 million in startup cofounded by UTs Mauro Ferrari
2. Iowa State chemist synthesizes carbohydrates, launches startup company
3. Case Western Reserve University grants option to startup Thermalin Diabetes Inc.
4. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
5. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
6. Luxembourg joins EMBL
7. Len Hunt Joins Gallup Consulting Group
8. FSU joins coalition working to improve nations power grid
9. GEN joins Charles Darwin 2009 celebration
10. Genomatix joins Illumina-Connect program
11. Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN ... STANDARD: QIA) today announced the U.S. launch of its ipsogen ... cleared by the U.S. Food and Drug Administration as a qualitative in vitro ... extracted from EDTA whole blood.* ... ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a ... the world’s food supply through enhancement of the gut microbiota, today announced the closing ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number of ...
Breaking Biology Technology: